Overview
The study, led by Dr Jake Ahern, uses computational modelling to investigate the interaction between biological rhythms and drug pharmacokinetics. The central finding: for medications with short half-lives, when a dose is taken may matter as much as how much is taken.
The model suggests that aligning medication timing with individual seizure patterns could improve outcomes by up to 20%, without changing the total daily dose.
This matters because it reinforces a principle at the heart of our work at Neuronostics: the epileptic brain is not static. Seizure risk fluctuates over hours, days, and longer cycles. Understanding these patterns creates opportunities for more personalised approaches to care.
Our BioEP technology analyses background EEG activity to provide objective assessments of epilepsy risk. As research like this advances, the goal of tailoring treatment timing to individual brain dynamics moves closer to reality.
The model suggests that aligning medication timing with individual seizure patterns could improve outcomes by up to 20%, without changing the total daily dose.
This matters because it reinforces a principle at the heart of our work at Neuronostics: the epileptic brain is not static. Seizure risk fluctuates over hours, days, and longer cycles. Understanding these patterns creates opportunities for more personalised approaches to care.
Our BioEP technology analyses background EEG activity to provide objective assessments of epilepsy risk. As research like this advances, the goal of tailoring treatment timing to individual brain dynamics moves closer to reality.
Authors
Jake Ahern, Udaya Seneviratne, Wendyl D’Souza, Mark J. Cook, John R. Terry
Found in
Frontiers in Network Physiology, Networks in the Brain System, Volume 5